CytomX医疗

CTMX NASDAQ
11.85
+0.06
+0.51%
盘后: 11.85 0 0.00% 17:04 07/16 EDT
开盘
11.80
昨收
11.79
最高
12.20
最低
11.65
成交量
32.66万
成交均量(3M)
38.94万
52周最高
27.20
52周最低
8.94
换手率
0.72%
市值
5.37亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供CytomX医疗 CTMX股票价格,CytomX医疗股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
展开 >

最近浏览

名称
价格
涨跌幅